期刊文献+

251例血液透析患者HBsAg与抗-HCV检测结果分析 被引量:2

The Status of Hepatitis B and Hepatitis C Virus Infection in Hemodialysis Patients
暂未订购
导出
摘要 目的分析血液透析患者乙型肝炎表面抗原(HBsAg)与丙型肝炎抗体(抗-HCV)检测结果,旨在寻求血透患者感染的依据,减少医源性感染。方法应用酶联免疫吸附法(EuSA)检测2006年12月份在我院进行血液透析的251例患者HBsAg与抗-HCV,并对透析1年以上的149例患者的肝炎标志物阳性率与透析年限、输血史、手术史的相关性进行分析。结果透析1年以上的149例患者中,HBsAg阳性者19例,阳性率为12.8%;抗-HCV阳性者29例,阳性率19.5%。HB—sAg、抗-HCV同时为阳性者仅1例(0.4%)。抗-HCV阳性率随透析年限、输血次数、手术次数增加而增高(P〈0.05),多因素非条件多元Logistic回归分析提示,透析年限是抗-HCV阳性率最有统计学意义的因素(OR〉I);而HBsAg阳性率与透析年限、输血、手术、性别的相关性均无明显统计学意义(P〉0.05)。结论透析年限、输血、手术与抗-HCV阳性率具有显著相关性,随着透析年限的增加抗-HCV阳性率上升,而与HBsAg阳性率无明显相关性。 Objective To investigate the status of Hepatitis B and Hepatitis C virus infection in hemodialysis (HD) patients so as to strengthen the preventive strategies for the infection. Method Serum samples of the HD patients in our dialysis center in December, 2006 were tested for HBsAg and anti-HCV antibody by ELISA. The correlation of the incidenal of HBsAg + and anti-HCV + with the duration on HD, the history of blood transfusion and surgicol intervetion were analyzed. Results A- mong 149 patients with duration on Hdmore than 12 months, the positive percentage of HBsAg and anti- HCV is 12. 8% (19/149) and 19. 5%(29/149) respectively, and the percentage of the concurrent infection is 0.4% (only 1/149). Single factor analysis showed that HCV infection was markedly associated with duration on HD, history and number of blood transfusion and surgicol intervetion (P〈 0. 05). Logistic regression analysis showed that the duration on HD is the most important factor (OR〉1). While single factor analysis showed that HBV infection was not significantly associated with the above factors(P〉0. 05). Conclusions The infection of the HBV virus in our dialysis center is relatively well controlled, while the control of the HCV virus infection has to be strengthened.
出处 《临床肾脏病杂志》 2008年第2期60-62,共3页 Journal Of Clinical Nephrology
关键词 血液透析 乙型肝炎表面抗原 丙型肝炎抗体 Hemodialysis HbsAg Anti-HCV
  • 相关文献

参考文献5

二级参考文献14

  • 1李金星 张彤 等.合格库血中HBVM、抗HCV,HBV-DNA及HCV-RNA的检出率分析[J].中华流行病学杂志,1997,18(1):58-58.
  • 2Goodnough L T, Shuck J M. Risks, options, and informed consent for blood transfusion in elective surgery [J]. Am J Surg, 1990, 159: 602.
  • 3Polesky H F, Hanson M R. Transfusion-associated hepatitis C virus (non-A, non-B) infection[J]. Arch Pathol Lab Med,1989, 113: 232.
  • 4Eonmoto N, Takada A, Nakao T, et al. There are two major types of hepatitis C virus in Japan[J]. Biochem Biopys Res Commun, 1990, 170.
  • 5Lin HH, Huang CC, Sheen IS, et al. Prevalence of antibodies to hepatitis C virus in the hemodialysis unit [J]. Am J Nephrol, 1991, 11: 192.
  • 6Covic A, Iancu L, Apetrei C, et al. Hepatitis virus infection in hemodialysis patients from moldavia. Nephrol Dial Transplant,1999,14:40-41.
  • 7Femandcz JL, Pino N, Lef L,et al. Serum hepatitis C virus RNA in anti-HCV negative hemodialysis patients. Dial Transplant, 1996,25:14-19.
  • 8Petrosillo N, Gilli P, Serraino D, et al. Prevalence of infected patients and understsaffing have a role in hepatitis C virus transmission in dialysis. Am J Kidney Dis,2001,37:1004.
  • 9邬祥惠.病毒性肝炎[A].见:陈灏珠主编.实用内科学第11版[C].北京:人民卫生出版社,2003.319-320.
  • 10肖观清,季大玺,陈朝红,宦红绨,谢红浪,刘芸,刘志红,黎磊石.血液透析患者和透析中心工作人员丙型肝炎病毒感染的研究[J].肾脏病与透析肾移植杂志,1997,6(6):525-530. 被引量:33

共引文献104

同被引文献21

  • 1丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量:733
  • 2SULOWICZ W,RADZISZEWSKI A,CHOWANIEC E. Scholarly review: hepatitis C virus infection in dialysis patients[J]. Hemodial Int, 2007,11 (3):286-295.
  • 3OLSEN SK,BROWN RS. Hepatitis B treatment: lessons for the nephrologists[J]. Kidney Int,2006,70(11):1897- 1904.
  • 4中国高血压防治指南修订委员会.中国高血压防治指南(2005年修订版)[J].高血压杂志,2005,.
  • 5K/DOQI. Clinical practice guide lines for cardiovascular disease in dialysis patients. Am J Kidney Dis,2005,45 : s1153.
  • 6Eknoyan G, Levin A,Levin NW, et al. Bone metabolism and dis- ease in chronic kidney disease. Am J Kidney Dis, 2003,42 (2): 197-201.
  • 7Coodman WG, Coldin J, Kuion BD, et al. Coronary artery calcifi- cation in young adults with end stage renal disease who are un- dergoing dialysis. New Engl Med, 2002,342 (20), : 1478-1483.
  • 8Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium. Phosphorus product with mortal- ity risk in chronic hemodialysis is patients: A national study. Am J Kidney Dis, 1998,31 (4) :607- 617.
  • 9Macdougall IC, Tucker B, Thompson J, et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kid Int. 1996, 50: 1694.
  • 10Collins AJ, Kasiske B, Herzog C, et al. United States renal data system 2006 annual data report. Am J Kidney Dis, 2007,49: s1- s296.

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部